Skip to main content
icon for Will AbbVie Q2 Global Skyrizi net revenues be above __?
Finanse·ABBV

Will AbbVie Q2 Global Skyrizi net revenues be above __?

icon for Will AbbVie Q2 Global Skyrizi net revenues be above __?
Finanse·ABBV

Will AbbVie Q2 Global Skyrizi net revenues be above __?

Jul 31

Jul 31

Jul 31

Jul 31

NOWE
Jul 31, 2026
Polymarket

$975 Wol.

Polymarket

$18B

$65 Wol.

25%

$19B

$65 Wol.

24%

$20B

$127 Wol.

7%

$21B

$0 Wol.

37%

$22B

$717 Wol.

8%

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Wolumen
$975
Data zakończenia
Jul 31, 2026
Rynek otwarty
Jul 18, 2026, 4:41 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Wolumen
$975
Data zakończenia
Jul 31, 2026
Rynek otwarty
Jul 18, 2026, 4:41 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Powiązane

icon for Will AbbVie Q2 Global Rinvoq net revenues be above $2.3B?

Will AbbVie Q2 Global Rinvoq net revenues be above $2.3B?

80%
icon for Will S&P Global (SPGI) Q2 Rating revenues be above $12.5B?

Will S&P Global (SPGI) Q2 Rating revenues be above $12.5B?

3%
icon for Will Verizon (VZ) Q2 total operating revenue be above $35B?

Will Verizon (VZ) Q2 total operating revenue be above $35B?

84%

Uważaj na linki zewnętrzne.

Często zadawane pytania

"Will AbbVie Q2 Global Skyrizi net revenues be above __?" to rynek prognoz na Polymarket z 5 możliwymi wynikami, gdzie traderzy kupują i sprzedają udziały na podstawie tego, co ich zdaniem się wydarzy. Obecny wiodący wynik to "$21B" z 37%, za nim "$18B" z 25%. Ceny odzwierciedlają zbiorowe prawdopodobieństwa w czasie rzeczywistym. Na przykład udział wyceniony na 37¢ implikuje, że rynek zbiorowo przypisuje 37% szansy na ten wynik. Te kursy zmieniają się ciągle, gdy traderzy reagują na nowe informacje. Udziały w poprawnym wyniku można wymienić na $1 za sztukę po rozstrzygnięciu rynku.

"Will AbbVie Q2 Global Skyrizi net revenues be above __?" to nowo utworzony rynek na Polymarket, uruchomiony Jul 18, 2026. Jako wczesny rynek, to Twoja okazja, aby być jednym z pierwszych traderów, którzy ustalą kursy i określą początkowe sygnały cenowe rynku. Możesz też dodać tę stronę do zakładek, aby śledzić wolumen i aktywność handlową w miarę rozwoju rynku.

Aby handlować na "Will AbbVie Q2 Global Skyrizi net revenues be above __?", przeglądaj 5 dostępnych wyników na tej stronie. Każdy wynik wyświetla bieżącą cenę reprezentującą implikowane prawdopodobieństwo rynku. Aby zająć pozycję, wybierz wynik, który uważasz za najbardziej prawdopodobny, wybierz "Tak", aby handlować na jego korzyść, lub "Nie", aby handlować przeciw niemu, wpisz kwotę i kliknij "Handluj". Jeśli wybrany wynik okaże się poprawny, Twoje udziały "Tak" wypłacą $1 za sztukę. Jeśli jest niepoprawny, wypłacą $0. Możesz też sprzedać swoje udziały w dowolnym momencie przed rozstrzygnięciem.

Obecnym faworytem dla "Will AbbVie Q2 Global Skyrizi net revenues be above __?" jest "$21B" z 37%, co oznacza, że rynek przypisuje 37% szansy na ten wynik. Następny najbliższy wynik to "$18B" z 25%. Te kursy aktualizują się w czasie rzeczywistym, gdy traderzy kupują i sprzedają udziały, odzwierciedlając najnowszy zbiorowy pogląd na to, co jest najbardziej prawdopodobne. Sprawdzaj regularnie lub dodaj tę stronę do zakładek, aby śledzić zmiany kursów.

Zasady rozstrzygania "Will AbbVie Q2 Global Skyrizi net revenues be above __?" określają dokładnie, co musi się wydarzyć, aby każdy wynik został ogłoszony zwycięzcą — w tym oficjalne źródła danych używane do ustalenia wyniku. Możesz przejrzeć pełne kryteria rozstrzygania w sekcji "Zasady" na tej stronie nad komentarzami. Zalecamy dokładne zapoznanie się z zasadami przed handlem, ponieważ określają one precyzyjne warunki, przypadki graniczne i źródła regulujące rozstrzyganie tego rynku.